You just read:

Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses

News provided by

Regeneron Pharmaceuticals, Inc.

27 Feb, 2017, 08:30 ET